ReviewBioMed research international2014
New SPECT and PET radiopharmaceuticals for imaging cardiovascular disease.
Review in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade.International journal of molecular sciences · 2022Pooled it
- The Return of Thallium-201 for American Patients: History, Radiopharmaceutical Features, and Current Applications.Current cardiology reports · 2026Review
- Synthesis and preliminary evaluation of cardiac imaging with [RSC pharmaceutics · 2025Article
- Comparison of global and regional myocardial blood flow quantification using dynamic solid-state detector SPECT and Tc-99 m-sestamibi or Tc-99 m-tetrofosmin in a routine clinical setting.The international journal of cardiovascular imaging · 2025Article
- Preclinical evaluation of [EJNMMI research · 2024Article
- Myocardial Functional Imaging in Pediatric Nuclear Cardiology.Journal of cardiovascular development and disease · 2023Review
- Druggability of Targets for Diagnostic Radiopharmaceuticals.ACS pharmacology & translational science · 2023Review
- Radiotracers to Address Unmet Clinical Needs in Cardiovascular Imaging, Part 1: Technical Considerations and Perfusion and Neuronal Imaging.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Review
- Is faster always better? What is the implication of a shorter time to imaging with tetrofosmin compared to sestamibi?Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021Article
- Cardiac hybrid imaging: novel tracers for novel targets.Journal of geriatric cardiology : JGC · 2021Article
- Quantification of Macrophage-Driven Inflammation During Myocardial Infarction withJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
- Feasibility of simultaneousJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021Observational
- Multimodal evaluation of the cerebrovascular reserve in Neurofibromatosis type 1 patients with Moyamoya syndrome.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021Observational
- Radioactive polymeric nanoparticles for biomedical application.Drug delivery · 2020Review
- Feasibility study of a point-of-care positron emission tomography system with interactive imaging capability.Medical physics · 2019Article
- Emerging Techniques for Cardiovascular PET.Cardiovascular innovations and applications · 2019Article
- Mitochondrial-Targeted Molecular Imaging in Cardiac Disease.BioMed research international · 2017Review
- Assessment of radiation dose in nuclear cardiovascular imaging using realistic computational models.Medical physics · 2015Article
- Stress echocardiography: what is new and how does it compare with myocardial perfusion imaging and other modalities?Current cardiology reports · 2015Review
- Molecular imaging of plaques in coronary arteries with PET and SPECT.Journal of geriatric cardiology : JGC · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nuclear cardiology has experienced exponential growth within the past four decades with converging capacity to diagnose and influence management of a variety of cardiovascular diseases. Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) with technetium-99m radiotracers or thallium-201 has dominated the field; however new hardware and software designs that optimize image quality with reduced radiation exposure are fuelling a resurgence of interest at the preclinical and clinical levels to expand beyond MPI. Other imaging modalities including positron emission tomography (PET) and magnetic resonance imaging (MRI) continue to emerge as powerful players with an expanded capacity to diagnose a variety of cardiac conditions. At the forefront of this resurgence is the development of novel target vectors based on an enhanced understanding of the underlying pathophysiological process in the subcellular domain. Molecular imaging with novel radiopharmaceuticals engineered to target a specific subcellular process has the capacity to improve diagnostic accuracy and deliver enhanced prognostic information to alter management. This paper, while not comprehensive, will review the recent advancements in radiotracer development for SPECT and PET MPI, autonomic dysfunction, apoptosis, atherosclerotic plaques, metabolism, and viability. The relevant radiochemistry and preclinical and clinical development in addition to molecular imaging with emerging modalities such as cardiac MRI and PET-MR will be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.